TLDR: Certara, a leader in model-informed drug development, has appointed Christopher Bouton, Ph.D., as its new Chief Technology Officer. This strategic move aims to accelerate the integration of advanced biosimulation technology and generative AI into Certara’s drug development platform, enhancing efficiency and effectiveness in bringing new medicines to market.
RADNOR, Pa. – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announced on July 31, 2025, the appointment of Christopher Bouton, Ph.D., as its new Chief Technology Officer. This key leadership addition is set to significantly bolster Certara’s technological innovation, particularly in the realm of AI-enabled biosimulation for drug discovery and development.
In his new role, Dr. Bouton will be responsible for leading Certara’s technology strategy and overseeing the development of a next-generation integrated model-informed drug development (MIDD) platform. This advanced platform will leverage generative AI and cutting-edge biosimulation technology to streamline the drug development lifecycle, from preclinical research to regulatory submissions.
Dr. Bouton brings extensive expertise in AI, computational biology, and enterprise analytics to Certara. He previously founded and served as CEO of Vyasa Analytics, a provider of scalable deep-learning software, which Certara acquired in 2022. His work at Vyasa enabled Certara’s software to make new predictions and answer complex questions across diverse data sources. Prior to Vyasa, he founded Entagen, an enterprise analytics software provider acquired by Thomson Reuters, and began his career in drug development as a computational biologist at Pfizer.
William F. Feehery, Certara’s Chief Executive Officer, praised Bouton’s appointment, stating, “Chris is a visionary leader who combines expertise in AI with experience in drug discovery and development. His leadership has been instrumental in expanding the adoption of AI-powered biosimulation and virtual trials, helping clients achieve greater success in bringing new medicines to patients faster and with greater confidence.”
Under Dr. Bouton’s guidance, Certara has already developed several AI-based products, including CoAuthor™, a generative AI solution designed for regulatory and medical writing. This demonstrates Certara’s commitment to integrating AI across its solutions to enhance efficiency and reduce human error.
Dr. Bouton emphasized the transformative potential of these integrated technologies, remarking, “Biosimulation combined with generative AI and machine learning is redefining how new medicines are discovered and developed, and is speeding timelines, reducing costs, and improving success rates. Leading Certara’s technology strategy to build the industry’s most advanced AI and model-informed drug development platform offers a unique opportunity to advance science and deliver better outcomes for patients worldwide.”
Also Read:
- FDA’s Embrace of Generative AI Prompts Call for Transparency and Validation in Pharmaceutical and Biotech Sectors
- Convexia, an AI-Powered Pharmaceutical Innovator, Emerges Backed by Y Combinator
Certara’s next-generation modeling platform is designed to integrate its scientific expertise, broad portfolio of solutions, and AI approaches to increase the efficiency and effectiveness of discovering and developing novel therapeutics. The company’s focus on biosimulation and generative AI positions it strongly within the healthcare industry, where technological advancements are crucial for accelerating the delivery of medicines to patients.
